Caris Life Sciences Inc
CAI27.940USD
+0.080+0.29%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
7.88BMarket Cap
LossP/E TTM
More Details of Caris Life Sciences Inc Company
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Caris Life Sciences Inc Info
Ticker SymbolCAI
Company nameCaris Life Sciences Inc
IPO dateJun 18, 2025
CEOHalbert (David Dean)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJun 18
Address750 W. John Carpenter Freeway
CityIRVING
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code75039
Phone18667718946
Websitehttps://www.carislifesciences.com/
Ticker SymbolCAI
IPO dateJun 18, 2025
CEOHalbert (David Dean)
Company Executives of Caris Life Sciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Vice Chairman of the Board
Vice Chairman of the Board
511.70K
-2.76%
Mr. Luke Power
Mr. Luke Power
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
99.57K
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Independent Director
Independent Director
16.13K
--
Mr. Nathan Burns
Mr. Nathan Burns
Independent Director
Independent Director
--
--
Mr. Vijay Mohan
Mr. Vijay Mohan
Independent Director
Independent Director
--
--
Mr. Danny Phillips
Mr. Danny Phillips
Independent Director
Independent Director
--
--
Dr. Lloyd B. Minor, M.D.
Dr. Lloyd B. Minor, M.D.
Independent Director
Independent Director
--
--
Mr. Peter M. Castleman
Mr. Peter M. Castleman
Lead Independent Director
Lead Independent Director
--
--
J. Russel Denton
J. Russel Denton
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Dr. Jeffrey L. (Jeff) Vacirca, M.D.
Dr. Jeffrey L. (Jeff) Vacirca, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Vice Chairman of the Board
Vice Chairman of the Board
511.70K
-2.76%
Mr. Luke Power
Mr. Luke Power
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
99.57K
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Independent Director
Independent Director
16.13K
--
Mr. Nathan Burns
Mr. Nathan Burns
Independent Director
Independent Director
--
--
Mr. Vijay Mohan
Mr. Vijay Mohan
Independent Director
Independent Director
--
--
Mr. Danny Phillips
Mr. Danny Phillips
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
178.18M
98.22%
International
3.22M
1.78%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Halbert (David D)
43.51%
Sixth Street Partners, LLC
8.64%
J.H. Whitney Capital Partners, LLC
7.18%
Castleman Peter M
3.68%
Coatue Management, L.L.C.
3.59%
Other
33.40%
Shareholders
Shareholders
Proportion
Halbert (David D)
43.51%
Sixth Street Partners, LLC
8.64%
J.H. Whitney Capital Partners, LLC
7.18%
Castleman Peter M
3.68%
Coatue Management, L.L.C.
3.59%
Other
33.40%
Shareholder Types
Shareholders
Proportion
Individual Investor
48.47%
Investment Advisor
20.21%
Hedge Fund
11.05%
Private Equity
10.52%
Investment Advisor/Hedge Fund
4.85%
Pension Fund
0.53%
Research Firm
0.29%
Sovereign Wealth Fund
0.13%
Bank and Trust
0.08%
Other
3.86%
Institutional Shareholding
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
172
130.04M
46.09%
+127.36M
2025Q2
45
192.42M
69.23%
+189.87M
2025Q1
3
2.55M
0.92%
+2.55M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Halbert (David D)
122.76M
43.65%
-141.96K
-0.12%
Aug 11, 2025
Sixth Street Partners, LLC
24.39M
8.67%
+24.39M
--
Jun 30, 2025
J.H. Whitney Capital Partners, LLC
20.26M
7.2%
+20.26M
--
Jun 30, 2025
Castleman Peter M
10.37M
3.69%
+10.34M
+32049.87%
Jun 18, 2025
Coatue Management, L.L.C.
10.14M
3.61%
+10.14M
--
Jun 30, 2025
Fidelity Management & Research Company LLC
8.61M
3.06%
+8.61M
--
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
7.30M
2.6%
+7.30M
--
Jun 30, 2025
Braidwell LP
7.32M
2.6%
+7.32M
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
6.76M
2.4%
+6.76M
--
Jun 30, 2025
Silver Lake Partners
5.29M
1.88%
+5.29M
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
0.67%
Texas Capital Texas Small Cap Equity Index ETF
0.52%
Renaissance IPO ETF
0.43%
RiverNorth Patriot ETF
0.3%
Franklin Genomic Advancements ETF
0.29%
Invesco Russell 1000 Equal Weight ETF
0.08%
Inspire 500 ETF
0.07%
T Rowe Price Small-Mid Cap ETF
0.05%
Texas Capital Texas Equity Index ETF
0.04%
Fidelity Nasdaq Composite Index ETF
0.02%
View more
ARK Genomic Revolution ETF
Proportion0.67%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.52%
Renaissance IPO ETF
Proportion0.43%
RiverNorth Patriot ETF
Proportion0.3%
Franklin Genomic Advancements ETF
Proportion0.29%
Invesco Russell 1000 Equal Weight ETF
Proportion0.08%
Inspire 500 ETF
Proportion0.07%
T Rowe Price Small-Mid Cap ETF
Proportion0.05%
Texas Capital Texas Equity Index ETF
Proportion0.04%
Fidelity Nasdaq Composite Index ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Caris Life Sciences Inc?
The top five shareholders of Caris Life Sciences Inc are:
Halbert (David D) holds 122.76M shares, accounting for 43.65% of the total shares.
Sixth Street Partners, LLC holds 24.39M shares, accounting for 8.67% of the total shares.
J.H. Whitney Capital Partners, LLC holds 20.26M shares, accounting for 7.20% of the total shares.
Castleman Peter M holds 10.37M shares, accounting for 3.69% of the total shares.
Coatue Management, L.L.C. holds 10.14M shares, accounting for 3.61% of the total shares.
Halbert (David D) holds 122.76M shares, accounting for 43.65% of the total shares.
Sixth Street Partners, LLC holds 24.39M shares, accounting for 8.67% of the total shares.
J.H. Whitney Capital Partners, LLC holds 20.26M shares, accounting for 7.20% of the total shares.
Castleman Peter M holds 10.37M shares, accounting for 3.69% of the total shares.
Coatue Management, L.L.C. holds 10.14M shares, accounting for 3.61% of the total shares.
What are the top three shareholder types of Caris Life Sciences Inc?
The top three shareholder types of Caris Life Sciences Inc are:
Halbert (David D)
Sixth Street Partners, LLC
J.H. Whitney Capital Partners, LLC
Halbert (David D)
Sixth Street Partners, LLC
J.H. Whitney Capital Partners, LLC
How many institutions hold shares of Caris Life Sciences Inc (CAI)?
As of 2025Q3, 172 institutions hold shares of Caris Life Sciences Inc, with a combined market value of approximately 130.04M, accounting for 46.09% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -23.14%.
What is the biggest source of revenue for Caris Life Sciences Inc?
In FY2025Q2, the -- business generated the highest revenue for Caris Life Sciences Inc, amounting to -- and accounting for --% of total revenue.
